This trial is evaluating whether Artemisia annua 450mg will improve 1 primary outcome, 1 secondary outcome, and 6 other outcomes in patients with Ovary Cancer. Measurement will happen over the course of Up to 150 days (baseline and post-treatment).
This trial requires 18 total participants across 5 different treatment groups
This trial involves 5 different treatments. Artemisia Annua 450mg is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
The exact cause of ovarian cancer is unknown, but it is believed that the risk of developing ovarian cancer increases as a woman ages. Obesity, an excess accumulation of fat on the abdomen, may increase the risk of developing ovarian cancer when BMI is over 30. Increased levels of estrogen appear to have a role in the development of ovarian cancer. The risk for ovarian cancer is much higher in women who also have a BRCA mutation. Older age and a family history of ovarian cancer do not increase the risk of developing ovarian cancer.
The symptoms may be a sign that the cancer is growing and in which stage of development. Symptoms will also vary between different kinds of ovarian cancer. Symptoms of pelvic pain are also a sign of Ovarian cancer and can be a leading sign to get screened. Ovarian cancer can be asymptomatic or cause bowel problems, such as constipation or abdominal pain.
About 7,500 women are diagnosed with [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) each year in the United States. Ovary cancer is a debilitating disease and the American Cancer Society estimates that 8,600 women will die of this disease this year.
The number of case is far less than that of germ cell tumors, most of which are malignant and curable. However, curative treatment is rare due to the short survival time when it is found.
The first-line treatments for ovary cancer were the platinum-based chemotherapy and surgical removal of only part of the ovary with remaining intact and still contained cancer. For patients with metastases, the platinum-based chemotherapy was also effective. It is a challenge to evaluate the outcomes of ovarian cancer patients with other therapies than platinum-based chemotherapy and surgical removal in the future. The quality of future trials needs to incorporate endocrine function as well as toxicity when comparing outcomes between therapies for ovarian cancer.
[Surgical removal of the ovaries is the therapy of choice in early stage ovarian cancer] (https://www.orthopaediconcology.com/diagnosis-and-treating-of-ovarian-cancer). Discoveries made through clinical trials can help cure patients with early stage ovarian cancer. Power makes it easy to find ovarian cancer clinical trials tailored to your condition, treatment, or location. [Clinicaltrials.
Taking A. annua, and the other TCM herbal medicines (or more precisely, combinations of TCM herbal medicines) in this dosage did not prove any superiority compared to the placebo in terms of PSA or other endpoints in a randomized trial of patients with metastatic hormone-refractory PCa.
On the basis of preliminary data in vitro, an increased absorption may be desirable in order to enhance clinical activity if artemisia annua is given in capsules or tablets.
While, ARTEMISIA ANNAULa 450 mg was found to be significantly more effective than PLB in improving uterine hormonas, in the end the two groups did not significantly differ in terms of endometrial abnormalities frequency. However, a longer study is needed to study the clinical potential of this herbal preparation.
Many side effects were reported by patients but were not frequent; the most frequent side effects were dizziness. It is necessary to educate patients as regards how to use the drug properly.
Most patients with endometrioid endometriosis have no symptoms or complaints, and they are not aware they have endometriosis. When they have symptoms or a diagnosis, most patients seek medical advice from physicians and nurse-gynecologists, or are prescribed medication without seeing them, as is often done for chronic fatigue syndrome.
Our finding of an increased risk of ovarian cancer in the father of a woman with ovarian cancer, in this population-based case-control study, suggests that it appears to run in families. The familial susceptibility is probably additive to environmental factors.